author-photo

Christopher Michael Pieczonka

Syracuse University

55

Papers

413

Citations

Citation Trend

Filter By

Papers (38) Sort By

Journal Conference Others

628P Universal germline testing of prostate cancer patients: Are genetic testing guidelines an aid or an impediment to precision therapy?

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Clinical study of VERU-111, an oral cytoskeletal disruptor, in metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Treatment decisions and outcomes for NCCN favorable intermediate-risk prostate cancer patients after receiving the 17-gene genomic prostate cancer score result.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
578MO Phase Ib/II study of sabizabulin (VERU-111), an androgen receptor transport disruptor, in men with metastatic castration resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent (ARTA)

2021 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Underdiagnosis of germline genetic prostate cancer: Are genetic testing guidelines an aid or an impediment?

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Clinical study of VERU-111, an oral cytoskeletal disruptor in men with metastatic Castration Resistant Prostate Cancer (mCRPC) who failed an androgen receptor targeting agent

2021 European Urology
Show All
- Source
- Cite
- Save
Citations (0)
The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial

2020 European Urology
Show All
- Source
- Cite
- Save
Citations (17)
DAROL: DARolutamide ObservationaL study patients in nonmetastatic castration-resistant prostate cancer (nmCRPC) patients.

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Reply to potential underestimation of cerebrovascular events in the PROVENGE registry for the observation, collection, and evaluation of experience data

2020 Cancer
Show All
- Source
- Cite
- Save
Citations (0)
A comparison of sipuleucel-T (sip-T) product parameters from two phase III studies: PROVENT in active surveillance prostate cancer and IMPACT in metastatic castrate-resistant prostate cancer (mCRPC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (3)